Literature DB >> 20122883

Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

Robert S Jansen1, Hilde Rosing, Wiete Kromdijk, Rob ter Heine, Jan Hm Schellens, Jos H Beijnen.   

Abstract

Emtricitabine (FTC) and tenofovir (TFV) are widely used antiviral agents that require intracellular phosphorylation to become active. This article describes the development and validation of an assay for the simultaneous quantification of FTC mono-, di- and triphosphate (FTC-MP, -DP and -TP), TFV and TFV mono- and diphosphate (TFV-MP and -DP) in peripheral blood mononuclear cells. Reference compounds and internal standards were obtained by thermal degradation of FTC-TP, TFV-DP, stable isotope-labeled TFV-DP and stable isotope-labeled cytosine triphosphate. Cells were lysed in methanol:water (70:30, v/v) and the extracted nucleotides were analyzed using weak anion-exchange chromatography coupled with tandem mass spectrometry. Calibration ranges in PBMC lysate from 0.727 to 36.4, 1.33 to 66.4 and 1.29 to 64.6 nM for FTC-MP, FTC-DP and FTC-TP and from 1.51 to 75.6, 1.54 to 77.2 and 2.54 to 127 nM for TFV, TFV-MP and TFV-DP, respectively, were validated. Accuracies were within -10.3 and 16.7% deviation at the lower limit of quantification at which the coefficients of variation were less than 18.2%. At the other tested levels accuracies were within -14.3 and 9.81% deviation and the coefficients of variation lower than 14.7%. The stability of the compounds was assessed under various analytically relevant conditions. The method was successfully applied to clinical samples. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20122883     DOI: 10.1016/j.jchromb.2010.01.002

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.

Authors:  Lane R Bushman; Jennifer J Kiser; Joseph E Rower; Brandon Klein; Jia-Hua Zheng; Michelle L Ray; Peter L Anderson
Journal:  J Pharm Biomed Anal       Date:  2011-06-06       Impact factor: 3.935

2.  Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.

Authors:  Joseph E Rower; Leah C Jimmerson; Xinhui Chen; Jia-Hua Zheng; Ariel Hodara; Lane R Bushman; Peter L Anderson; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

3.  Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.

Authors:  Hideaki Okochi; Alexander Louie; Nhi Phung; Kevin Zhang; Regina M Tallerico; Karen Kuncze; Matthew A Spinelli; Catherine A Koss; Leslie Z Benet; Monica Gandhi
Journal:  Drug Test Anal       Date:  2021-04-13       Impact factor: 3.234

4.  Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses.

Authors:  Ron J Keizer; Robert S Jansen; Hilde Rosing; Bas Thijssen; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Pharmacol Res Perspect       Date:  2015-03-25

5.  Application of High-Performance Liquid Chromatography for Simultaneous Determination of Tenofovir and Creatinine in Human Urine and Plasma Samples.

Authors:  Patrycja Olejarz; Grażyna Chwatko; Paweł Kubalczyk; Krystian Purgat; Rafał Głowacki; Kamila Borowczyk
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-05

Review 6.  Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues.

Authors:  Maria A Acquavia; Luca Foti; Raffaella Pascale; Antonia Nicolò; Vincenzo Brancaleone; Tommaso R I Cataldi; Giuseppe Martelli; Laura Scrano; Giuliana Bianco
Journal:  Talanta       Date:  2020-11-05       Impact factor: 6.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.